AzTrials
AzTrials

Scoliosis CorrectionPhase 2/3IV-KIDSNCT07217873

IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study

A Phase 2/3 study testing Ferric carboxymaltose IV in people with Scoliosis Correction and Iron Deficiency, run by Columbia University at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Adolescents and young adults undergoing spinal fusion surgery for the correction of scoliosis and other spinal deformity are at high risk of perioperative iron deficiency and anemia, yet the means and evidence for optimizing iron status have not been described in this setting. Read more about this study

Who is it for?
Ages 10 to 19 years
What is being tested?
Ferric carboxymaltose IV
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
120 participants
Where
1 siteUnited States
Study dates
21 Nov 2025to 31 Oct 2027
Phase
Phase 2/3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 10 to 19 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • 10 -19 years old
  • diagnosis of scoliosis or kyphosis
  • scheduled for imminent spinal fusion procedure (<6 weeks) at MS-CHONY
  • Iron deficiency or hypoferritinemia, defined as serum ferritin less than or equal to 50 μg/L

Who cannot join

  • C-reactive protein > 10 mg/L
  • receiving nutritional support by report in the medical chart
  • self-reported history of hypersensitivity reaction to iron-containing supplements
  • self-reported history of receiving intravenous iron supplements
  • self-reported history of iron overloaded state such as hereditary hemochromatosis or hemosiderosis
  • objection to receiving red blood cell transfusions
Show all 9Show fewer
  • current pregnancy (identified by self-report or documentation of preoperative screening test in the medical record)
  • prisoners
  • patient or parent decides against study participation

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Lisa D Eisler, M.D. contact

212-305-2413

ldl2113@cumc.columbia.edu

United States1 site, 1 recruiting
  • Columbia University Irving Medical Center

    New York, New York, 10032

    Recruiting

Other trials in United States

About this study

Official title: IntraVenous Iron in Kids With Iron Deficiency and Scoliosis

Adolescents and young adults undergoing spinal fusion surgery for the correction of scoliosis and other spinal deformity are at high risk of perioperative iron deficiency and anemia, yet the means and evidence for optimizing iron status have not been described in this setting. The proposed study is a randomized controlled trial of preoperative intravenous iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood cell transfusion and diminished postoperative cognitive and physical capacity in this vulnerable population. Building evidence for patient blood management interventions such as iron supplementation is vital to ensuring high quality care of surgical patients and may reduce unnecessary transfusions amid recent blood shortages.

Read the detailed description

Adolescents undergoing spinal fusion surgery for scoliosis and/or kyphosis are poised to benefit from preoperative iron supplementation. Spinal fusion carries a risk of large surgical blood losses and perioperative red blood cell transfusion, which are associated with adverse outcomes in this population. These patients are mostly adolescent females, a group more susceptible to iron deficiency and resulting anemia at baseline due to iron losses with menses, and who suffer an additional insult to iron stores during surgery. Nevertheless, iron status is not routinely monitored in this setting and there is no standard of care for preoperative iron supplementation. Iron is a nutritionally essential trace element important not only for red blood cell production, but also for muscle function and neurotransmitter synthesis and signaling. Therefore, supplementation of poor iron status is an important target for optimizing hemoglobin prior to surgery, reducing transfusion rates and associated complications such as alloimmunization, and improving patient outcomes. On its own and as the primary cause of anemia, iron deficiency was identified as the only risk factor for transfusion which is modifiable preoperatively. In addition, iron supplementation is shown to alleviate impairments of physical and cognitive capacity associated with even mild forms of iron deficiency in adolescent and young adult females. A pilot study conducted at Columbia University Irving Medical Center identified iron deficiency in 36% of scoliosis patients prior to surgery, with preoperative iron status highly correlated with iron status during surgical recovery. Consequently, the investigators plan to examine iron deficiency as a modifiable risk factor for transfusion and impaired postoperative cognitive and physical capacity in this vulnerable population. Previous trials of brief iron interventions in high-risk adult surgical patients, mostly with unknown iron status, do not inform the care of adolescents and were not designed to address postoperative functional outcomes. The investigators will therefore perform a single-center randomized controlled trial in which adolescents with scoliosis and/or kyphosis identified using physiologically-based serum markers of poor iron status will be randomized to a one time preoperative dose of IV ferric carboxymaltose or placebo, to test the hypotheses that preoperative iron supplementation 1) reduces the rate of red blood cell transfusion, 2) improves postoperative neurocognition compared to a preoperative baseline, and 3) improves patient reported physical functioning during recovery. This study aims to improve outcomes in this vulnerable population and provide evidence for patient blood management approaches to reduce transfusions amid recent severe blood shortages.

Being tested
Ferric carboxymaltose IV, Normal Saline (Placebo)
Keywords
scoliosis, iron deficiency, blood transfusion, spinal fusion, iron supplementation
Medical subject headings
Iron Deficiencies, Scoliosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ferric carboxymaltose IVDrug

    Ferric carboxymaltose is an intravenous treatment for iron deficiency.

  • Normal Saline (Placebo)Drug

    Normal saline is the recommended diluent for ferric carboxymaltose, and on its own serves as the placebo control for this study.

Study groups in NCT07217873
Study groupRoleWhat they receive
Intravenous ferric carboxymaltoseExperimentalParticipants will receive ferric carboxymaltose, 15mg/kg up to 750mg intravenously, on the morning of surgery.
Receives: Drug: Ferric carboxymaltose IV
Intravenous normal salinePlacebo comparatorPatients will receive normal saline, intravenously, on the morning of surgery.
Receives: Drug: Normal Saline (Placebo)
Observational follow-upNo interventionParticipants who do not qualify for randomization may be invited to complete study measures through postoperative follow-up as part of an observational study.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of perioperative RBC transfusion in iron deficient scoliosis patients undergoing spinal fusion

    The patients that received a red blood cell transfusion either during procedure or postoperatively during their surgical hospitalization will be tallied.

    Measured: 4-30 days

Secondary outcomes (3)
  1. Percentage of Patients that experienced postoperative change in neurocognitive function

    The Cognitive Battery of the NIH Toolbox is a brief, valid, and reliable instrument designed to provide outcome measures in epidemiologic and longitudinal research that can be used for comparisons across a wide range of studies and populations. Individual measure scores in the battery reflect Executive Function, Attention, Verbal and Nonverbal Memory, Language, Processing Speed, and Working Memory, yielding a composite score. This composite is scored on a T-score, with 100 representing the mean normalized by age and education level, and a standard deviation of 10. A score of 100 indicates performance that was at the national average for the test-taking participant's age. Scores of 85 or lower indicate below average cognitive function. A decline of function is measured by comparing the mean change from baseline in the Cognitive Function Composite Scores in the study groups.

    Measured: 2 to 3 months

  2. Percentage of patients that experienced postoperative change in self-reported physical capacity

    The PROMIS pediatric measures are a NIH Roadmap initiative to provide access to valid and reliable self-reported measures of health-related quality of life in children and adolescents. The PROMIS measures are scored on a T-score metric, where a score of 50 and standard deviation of 10 represents the average score for the general population in the United States. Higher PROMIS symptom scores indicate increased symptom burden, and higher PROMIS function scores indicate increased functioning. Decline would be identified through a mean change (decrease) from baseline in the Physical Functioning - Mobility scores; with secondary hypotheses for Physical Functioning - Upper Extremity, Physical Activity, and Fatigue.

    Measured: 2 to 3 months

  3. Volume of perioperative RBC transfusion

    The volume that each patient receives either during procedure or postoperatively during surgical hospitalization will be summed and average calculated.

    Measured: 4 to 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Oct 2025
  2. Study start21 Nov 2025
  3. Primary completion31 Aug 2027 (estimated)
  4. Study completion31 Oct 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized, double-blind, placebo controlled trial
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07217873
Sponsor's protocol ID
AAAV9024
Acronym
IV-KIDS
Status last verified
Nov 2025
First submitted
14 Oct 2025
Last updated
26 Nov 2025
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided: We will make the determination to share or not share IPD at a later date.

Publications

  • Qiu A, Fliginger D, Feit Y, Hassan F, Lenke LG, Li G, Hod EA, Eisler L. Estimating the prevalence of preoperative iron deficiency and its impact on red blood cell transfusion in adolescents undergoing scoliosis surgery: A pilot study. Transfusion. 2025 May;65(5):851-857. doi: 10.1111/trf.18246. Epub 2025 Apr 7.

    PubMed 40191932

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Ferric carboxymaltose IV in people with Scoliosis Correction and Iron Deficiency, run by Columbia University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 26 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Lisa D Eisler, M.D. (212-305-2413, ldl2113@cumc.columbia.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of perioperative RBC transfusion in iron deficient scoliosis patients undergoing spinal fusion (time frame: 4-30 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07217873, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in